A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesPrognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabBurkitt lymphoma in adolescents and young adults: management challenges.Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Biomarkers of HIV-associated Cancer.Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialB-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.Controversies in the treatment of Burkitt lymphoma in AIDSConcurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchThe pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.Bilateral breast masses with a rare etiology.Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort StudyImproved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature.Molecular cytogenetics of lymphoma: where do we stand in 2010?Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care.The role of hematopoietic SCT in adult Burkitt lymphoma.The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Current perspectives in genetics of "double-hit" lymphoma with possible clinical implications.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Double hit lymphoma - a case of unusual response after sequential aggressive chemotherapy and review of the literature.Treating Burkitt Lymphoma in Adults.Double hit lymphoma: from biology to therapeutic implications.Diagnosis and treatment of CD20 negative B cell lymphomas.Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature
P2860
Q24597424-80E00D55-0EBE-418A-81F3-173FF2A94036Q27306995-DAFEBFE7-BADF-4361-A490-E26710C5F9D4Q28256567-B26DE6F6-58EE-498F-B29D-F9666C53361DQ30238965-0F1943F5-40D0-46E2-8296-18BF71208E14Q30540646-BB18288C-C890-4947-AAC0-839E171C62B4Q33411059-AA05F5EA-E028-4806-AEC5-3AC69664F59BQ33560762-2F3BA2A9-E0BB-4EB7-B422-22304A446138Q33583302-926D149F-8964-433E-BA61-BE688A4B5B72Q33856851-4B2E0566-443C-4888-8C02-911D482080F2Q34018599-CB0A8DA6-F7DC-49BC-A4AB-810F2A15D32CQ34606414-6B1AFC58-D0B1-46D1-BFB9-11BFD81B0FFFQ34627112-82378468-1C6D-4F93-9C2A-C94695D1BEA4Q34737471-FF939DB2-B226-426E-891D-0D8334B3F7CAQ35153156-27C8B9B2-10EE-464A-AF19-D2013457518AQ35180822-93DD9012-DC8E-4C18-86E1-ACC7D3F55BDBQ35236068-A72D965C-46A1-4E61-801D-D735ADC25930Q35384536-BE74B99E-BA74-47A8-A559-BF1A133A6D16Q35429833-CE239FF4-52FD-443C-AB87-7F49457A791EQ35881523-3BF7F648-1CCA-401B-9E94-6C3FBCEBE336Q36151295-54CD73BB-A75A-47B1-9B09-CDD1B78574D4Q36267666-9941DAEA-A4DE-49EB-B532-00346B04C634Q36557201-7C2D63BC-A6BA-4E62-93C0-6E84B2D2023DQ36620507-BD1FFD9E-F47F-464B-B292-62DF09A7E22BQ37166668-3173978E-CB40-4DB3-964A-C0FBDDA69EF8Q37301300-939F127E-C8EF-4AEF-9756-F2C20C9B1D45Q37613872-2A995B52-601C-4040-B278-EEA12A30FB56Q37624237-C47F5269-C960-42E4-A755-61D1D6671020Q37718297-51A5FC9F-1E38-45C0-90F1-744261158D22Q37783612-7702281B-8DD2-49AC-940B-1A41772F6B40Q37831961-A5DDE934-0A89-47D3-8CD5-B512116A6033Q37831962-E2636B79-C7CC-4CB2-9D0D-27E4EBC6FD53Q38031733-9F900883-717E-4F46-93B4-D6C68E50A47EQ38124735-3E7E0B3E-6DA5-4184-9F14-66CA6DA6136CQ38162809-400B3EF2-0595-486C-9334-BC428DA2CC79Q38242272-0690ED91-B545-4FB9-B6F3-491D43E09B66Q38261916-5F699E98-EF8E-40CA-86CC-9BC78A7043DDQ38503297-4158D8F8-8FC0-4B71-B6F8-EC647BA97E9BQ38831667-A1E60232-745A-47B6-B4DA-235D1A36ACBEQ39132786-814BE073-FB18-4659-9362-F5867E73A9D9Q39270336-F8B46EC2-D4D2-4A56-916E-3E2EC50B09F3
P2860
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A prospective clinicopathologi ...... riteria (MRC/NCRI LY10 trial).
@en
type
label
A prospective clinicopathologi ...... riteria (MRC/NCRI LY10 trial).
@en
prefLabel
A prospective clinicopathologi ...... riteria (MRC/NCRI LY10 trial).
@en
P2093
P2860
P1433
P1476
A prospective clinicopathologi ...... riteria (MRC/NCRI LY10 trial).
@en
P2093
Andrew S Jack
Australasian Leukaemia and Lymphoma Group
Claire L Yule
Graham M Mead
Jan Walewski
John A Radford
Sally P Stenning
Sharon L Barrans
Simon M Clawson
P2860
P304
P356
10.1182/BLOOD-2008-03-145128
P407
P577
2008-07-08T00:00:00Z